Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Chronic hyperinsulinemia accelerates adipose senescence via mitochondrial dysfunction and cGAS-STING signalling.

The Journal of endocrinology·2026
Same author

Meta-analysis of Early Risk Factors Associated with Cerebrovascular Diseases.

Current neurovascular research·2026
Same author

Association of duration of untreated Dhat Syndrome on coping mechanism, quality of life and disability in Dhat Syndrome: A cross-sectional study.

Indian journal of psychiatry·2026
Same author

Cognitive impairment in tuberculous meningitis: Systematic review & meta-analysis.

The Indian journal of tuberculosis·2026
Same author

Punding in dementia: an insight into its occurrence, clinical characteristics, treatment, and outcome.

Neurodegenerative disease management·2026
Same author

Periodic catatonia in the elderly: A case series highlighting the diagnostic challenge between delirium and catatonia.

Industrial psychiatry journal·2026

Video Experimental Relacionado

Updated: Sep 10, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K

Una serie de casos de penfigoide bullosa asociada con vildagliptina - Efecto secundario raro

Mohit Kumar Shahi1, J V Ashwin1, Astha Singh2

  • 1Department of GMH, King George Medical University, Lucknow, Uttar Pradesh, India.

Indian journal of pharmacology
|August 22, 2025
PubMed
Resumen

La vildagliptina, un agente hipoglucémico oral común, puede desencadenar el pemfigoide bulloso, una afección cutánea que produce ampollas. Esta serie de casos destaca a tres pacientes que desarrollaron este trastorno autoinmune después de comenzar el tratamiento con vildagliptina para la diabetes tipo 2.

Área de la Ciencia:

  • Endocrinología
  • Dermatología
  • Inmunología

Sus antecedentes:

Palabras clave:
Pemphigoides de las abejasla diabetesDipeptidilpeptidasa-4 y sus derivadosLa vildagliptina es un fármaco

Más Videos Relacionados

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.1K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

340

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.1K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

340
  • La vildagliptina es un agente hipoglucémico oral (OHA) de la clase de inhibidores de la dipeptidilpeptidasa-4 (DPP-4).
  • Los inhibidores de la DPP-4 se utilizan ampliamente para el tratamiento de la diabetes mellitus tipo 2 (DM2).
  • El penfigoide bulloso (BP) es una enfermedad autoinmune con ampollas que afecta a la piel y las membranas mucosas.